MEDINDIA
English
हिन्दी
Español
français
中文
Email
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Fludarabine.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Fludarabine.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Fludarabine.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Fludarabine is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Fludarabine.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Fludarabine is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Fludarabine is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Fludarabine.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Fludarabine.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fludarabine.
Clozapine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Fludarabine.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Fludarabine.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Fludarabine.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Fludarabine.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Fludarabine.
Digoxin
Digoxin may decrease the cardiotoxic activities of Fludarabine.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Fludarabine.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Fludarabine.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Fludarabine.
Fingolimod
Fludarabine may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Fludarabine is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Hepatitis B Vaccine (Recombinant).
Imatinib
Imatinib may decrease the myelosuppressive activities of Fludarabine.
Leflunomide
The risk or severity of adverse effects can be increased when Fludarabine is combined with Leflunomide.
Lipegfilgrastim
Fludarabine may increase the myelosuppressive activities of Lipegfilgrastim.
Natalizumab
The risk or severity of adverse effects can be increased when Fludarabine is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Fludarabine.
Ouabain
Ouabain may decrease the cardiotoxic activities of Fludarabine.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fludarabine.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Fludarabine.
Pentostatin
The risk or severity of adverse effects can be increased when Fludarabine is combined with Pentostatin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludarabine.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Fludarabine.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Fludarabine is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Fludarabine is combined with Rabies virus inactivated antigen, A.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Fludarabine.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Fludarabine is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Fludarabine is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Fludarabine is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludarabine.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Fludarabine.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Fludarabine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Fludarabine may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Fludarabine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Fludarabine is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Fludarabine is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Fludarabine is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Fludarabine is combined with Yellow Fever Vaccine.
